BIX01294 enhances the cytotoxic effects of temozolomide in GBM stem-like cells, even in the absence of changes in pluripotency markers NANOG, SOX2, and CD133, or methylation of NANOG and SOX2 gene promoters. This evidence concerns the gene NANOG and glioblastoma.